X4 Pharmaceuticals Files 8-K: Agreements, Equity Sales, Officer Changes

TL;DR

X4 Pharma 8-K: New deals, stock sales, exec shakeup. Watch closely.

AI Summary

On August 11, 2025, X4 Pharmaceuticals, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and changes in its board and officer composition, including compensatory arrangements. This filing also includes other events and financial statements/exhibits.

Why It Matters

This 8-K filing indicates significant corporate activity for X4 Pharmaceuticals, including new agreements and potential equity dilution, which could impact investors.

Risk Assessment

Risk Level: medium — The filing details material agreements, unregistered equity sales, and changes in officers, all of which can introduce financial and operational risks.

Key Numbers

• 20250811 — Report Date (The filing pertains to events on this date.)
• 20250812 — Filing Date (The report was officially filed on this date.)

Key Players & Entities

• X4 Pharmaceuticals, Inc. (company) — Registrant
• August 11, 2025 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• 001-38295 (commission_file_number) — SEC File Number
• 27-3181608 (ein) — IRS Employer Identification No.

FAQ

Key Financial Figures

• $0.001 — ich registered Common Stock, par value $0.001 per share XFOR The Nasdaq Stock Market
• $1.42 — "Common Stock"), at a purchase price of $1.42 per Share, which represents the officia
• $1.419 — of Common Stock at a purchase price of $1.419 per Pre-Funded Warrant. The price per P
• $60 m — the Private Placement of approximately $60 million, before deducting the placement a
• $457,266 — f 340,000 (GBP) (equal to approximately $457,266), a target annual bonus opportunity of
• $450,000 — other things, an annual base salary of $450,000, a target annual bonus opportunity of 4
• $495,000 — other things, an annual base salary of $495,000, a retention and performance-

Filing Documents

• xfor-20250811.htm (8-K) — 81KB
• ex-41formofaugust2025prexf.htm (EX-4.1) — 118KB
• ex-101securitiespurchaseag.htm (EX-10.1) — 279KB
• ex-102registrationrightsag.htm (EX-10.2) — 135KB
• ex-103amendmentto2019induc.htm (EX-10.3) — 4KB
• ex-991pressreleaseaugust12.htm (EX-99.1) — 17KB
• image_0a.jpg (GRAPHIC) — 0KB
• x4logo.jpg (GRAPHIC) — 10KB
• 0001628280-25-039770.txt ( ) — 896KB
• xfor-20250811.xsd (EX-101.SCH) — 2KB
• xfor-20250811_lab.xml (EX-101.LAB) — 23KB
• xfor-20250811_pre.xml (EX-101.PRE) — 13KB
• xfor-20250811_htm.xml (XML) — 3KB

01 Entry into a Definitive Material Agreement

Item 1.01 Entry into a Definitive Material Agreement. Securities Purchase Agreement On August 11, 2025, X4 Pharmaceuticals, Inc. (the "Company") entered into a securities purchase agreement (the "Securities Purchase Agreement") with several institutional accredited investors (the "Investors"), pursuant to which the Company agreed to issue and sell to the Investors in a private placement (the "Private Placement") (i) an aggregate of 11,040,776 shares (the "Shares") of the Company's common stock, par value $0.001 per share (the "Common Stock"), at a purchase price of $1.42 per Share, which represents the official closing price of the Common Stock on the Nasdaq Capital Market on August 11, 2025, and (ii) with respect to certain Investors, in lieu of Shares, pre-funded warrants (the "Pre-Funded Warrants") to purchase an aggregate of 31,234,731 shares of Common Stock at a purchase price of $1.419 per Pre-Funded Warrant. The price per Pre-Funded Warrant represents the price of $1.42 per Share to be sold in the Private Placement, minus the $0.001 per share exercise price of each such Pre-Funded Warrant. The Pre-Funded Warrants are exercisable at any time after their original issuance and will not expire until exercised in full. The Pre-Funded Warrants to be issued in the Private Placement will provide that a holder of the Pre-Funded Warrants will not have the right to exercise any portion of its Pre-Funded Warrants if such holder, together with its affiliates, would beneficially own in excess of 4.99% (or, upon election by such holder, 9.99%) of the number of shares of the Company's Common Stock outstanding immediately after giving effect to such exercise (the "Beneficial Ownership Limitation"); provided, however, that each holder may increase or decrease the Beneficial Ownership Limitation up to, and no higher than 19.99%, provided that any increase will not be effective until the 61st day following notice to the Company. The Private Placement is expected to close

02 Unregistered Sales of Equity Securities

Item 3.02 Unregistered Sales of Equity Securities. To the extent required by Item 3.02 of Form 8-K, the information contained above in Item 1.01 relating to the Private Placement is hereby incorporated by reference into this Item 3.02. Based in part upon the representations of the Investors in the Securities Purchase Agreement, the offering and sale of the securities will be made in reliance on the exemption afforded by Regulation D under the Securities Act of 1933, as amended (the "Securities Act"), and corresponding provisions of state securities or "blue sky" laws. The securities will not be registered under the Securities Act or any state securities laws and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from the registration requirements. The sale of the securities will not involve a public offering and will be made without general solicitation or general advertising. The Investors represented that they are accredited investors, as such term is defined in Rule 501(a) of Regulation D under the Securities Act, and that they are acquiring the securities for investment purposes only and not with a view to any resale, distribution or other disposition of the securities in violation of the U.S. federal securities laws. A Form D filing will be made following the closing of the Private Placement in accordance with the requirements of Regulation D. Neither this Current Report on Form 8-K nor any exhibit attached hereto is an offer to sell or the solicitation of an offer to buy shares of Common Stock or other securities of the Company. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) Departure of President, Chief Executive Officer and Principal Executive Officer On August 11, 2025, Paula Ragan, Ph.D. notified the Company's board of directors (the "Board") of her resignation as President, C

View Full Filing

View this 8-K filing on SEC EDGAR